Tandem Diabetes Care Expands Insulin Pump Support for Libre 3 Plus in Europe
Tandem Diabetes Care (TNDM) announced expanded connectivity of its t:slim X2 insulin pump with Abbott's FreeStyle Libre 3 Plus CGM in five European countries. The news comes as TNDM shares have fallen 28.49% year-to-date.
Key Numbers
Tandem Diabetes Care (TNDM) announced that its t:slim X2 insulin pump with Control-IQ+ technology now integrates with Abbott's (ABT) FreeStyle Libre 3 Plus continuous glucose monitor (CGM) across five European countries. The expansion follows a 28.49% year-to-date decline in TNDM shares to $15.41, raising questions about valuation.
The Product
The t:slim X2 with Control-IQ+ is a hybrid closed-loop system that automatically adjusts insulin delivery based on CGM readings. Connectivity with Libre 3 Plus offers users improved accuracy and eliminates fingerstick calibration.
Pricing and Availability
Tandem has not disclosed specific pricing for the new European markets. The system is currently available in Germany, France, Italy, Spain, and the Netherlands, with plans for further expansion.
Competition
Tandem faces competition from Medtronic and Insulet (Omnipod), as well as CGM systems from Dexcom. The Abbott partnership strengthens its position in the growing CGM market.
Potential Impact on the Company
This expansion could boost Tandem's European market share and revenue, though the stock has yet to react positively. The financial impact will depend on adoption rates and competitive dynamics.
Frequently Asked Questions
Found this useful? Share it